Schering-Plough's TEMODAL Capsule for Glioblastoma Multiforme Granted Priority Review by Government.Tokyo, Japan, Nov 2, 2005 - (JCNN JCNN Japan Corporate News Network ) - Schering-Plough K.K. has announced that the Ministry of Health, Labor and Welfare (MHLW) has granted the company with a priority review status for TEMODAL Capsule, an antitumor agent imported by Schering-Plough. TEMODAL (temozolomide) Capsule is an oral, cytotoxic alkylating agent indicated for treating glioblastoma multiforme (GBM GBM 1 Glioblastoma multiforme, see there 2. Glomerular basement membrane ). In Japan, it is estimated that about 2,500 people develop GBM annually, of whom about 2,200 people are diagnosed as anaplastic an·a·plas·tic adj. 1. Relating to the surgical restoration of a lost or absent part. 2. Of, relating to, or characterized by cells that have become less differentiated. anaplastic 1. astrocytoma astrocytoma /as·tro·cy·to·ma/ (as?tro-si-to´mah) a tumor composed of astrocytes; the most common type of primary brain tumor and also found throughout the central nervous system, classified on the basis of histology or in order of . Initially approved in the EU in January 1999, temozolomide is currently approved in 77 countries worldwide. Source: JCN http://www.japancorp.net Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion